Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585674 | 1.00 | CETP (0.64) | CETP | |
| SCHEMBL993324 | 0.92 | CETP (0.65) | CETP | |
| SCHEMBL6182936 | 0.92 | CETP (0.65) | CETP | |
| SCHEMBL6480622 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL993420 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL6228889 | 0.90 | CETP (0.79) | CETP | |
| SCHEMBL992510 | 0.90 | CETP (0.79) | CETP | |
| SCHEMBL1899786 | 0.89 | CETP (0.64) | CETP | |
| SCHEMBL993025 | 0.88 | CETP (0.70) | CETP | |
| SCHEMBL6393539 | 0.88 | CETP (0.70) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-7071210-B2 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. (US) | 2006-07-04 | — | — | US | claimed |
| EP-1519752-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | claimed |
| EP-1453544-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1114032-B1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | claimed |
| WO-2004004777-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | claimed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| EP-2258352-B1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | BEND RES INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-6489478-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INHIBITORS AND THE USE OF SUCH INHIBITORS TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN | PFIZER INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | disclosed |
| EP-1114032-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000017165-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885 |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | CETP 1/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.